|  | 
| MechanismHMG-CoA reductase inhibitors [+1]  | 
|  | 
|  | 
|  | 
| Inactive Indication- | 
| Drug Highest PhaseApproved | 
| First Approval Ctry. / Loc.South Korea | 
| First Approval Date01 May 2018 | 
|  | 
| MechanismHMG-CoA reductase inhibitors [+1]  | 
| Active Org.- | 
|  | 
| Active Indication- | 
|  | 
| Drug Highest PhasePending | 
| First Approval Ctry. / Loc.- | 
| First Approval Date20 Jan 1800 | 
A Randomized, Open-label, Single Dose, Crossover Study to Compare the Pharmacokinetic Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 (1000/10mg) in Healthy Male Volunteers.
A randomized, open-label, single dose, crossover study to compare the pharmacokinetic characteristics of the co-administration of metformin SR and rosuvastatin and JLP-1310 in healthy male volunteers.
100 Clinical Results associated with HMGCR x PRKAB1
100 Translational Medicine associated with HMGCR x PRKAB1
0  Patents (Medical) associated with HMGCR x PRKAB1